CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
CytoDyn has dosed the first patient in its Expanded Access Program for leronlimab, targeting triple-negative breast cancer patients who have exhausted other treatment options. The program aims to provide compassionate access while gathering real-world data on the CCR5 inhibitor's biological activity and its potential synergy with immune checkpoint therapies.
Key figures
- Patients enrolled eap
- 1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.